Drug interactions with patient-controlled analgesia

Clinical Pharmacokinetics

Volumn 41, Issue 1, 2002, Pages 31-57

  Lötsch, Jörn ^a   Skarke, Carsten ^a   Tegeder, Irmgard ^a   Geisslinger, Gerd ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALFENTANIL; ALKYLATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CODEINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIHYDROCODEINE; DIPYRONE; FENTANYL DERIVATIVE; GLYCOPROTEIN P; HYDROMORPHONE; KETOROLAC; METHADONE; MORPHINE DERIVATIVE; NALBUPHINE; OPIATE AGONIST; OROSOMUCOID; PETHIDINE; PIROXICAM; QUINIDINE; RIFAMPICIN; SUFENTANIL; TRAMADOL; UNINDEXED DRUG;

DROWSINESS; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; GASTROINTESTINAL TRACT; HUMAN; MEMBRANE TRANSPORT; NAUSEA; PATIENT CONTROLLED ANALGESIA; PRIORITY JOURNAL; PRURITUS; REVIEW; SEDATION; THROMBOCYTE AGGREGATION;

EID: 0036168920     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241010-00004     Document Type: Review

References (403)

1. Patient-controlled intravenous analgesia for postoperative pain relief
2. Addition of morphine to intra-articular bupivacaine does not improve analgesia following knee joint replacement
3. Bupivacaine infiltration into the neurovascular bundle of the prostatic nerve does not improve postoperative pain or recovery following transvesical prostatectomy
4. Epidural and subcutaneous morphine in the management of cancer pain: A double-blind cross-over study
5. Effect of patient-controlled analgesia on plasma catecholamine, cortisol and glucose concentrations after cholecystectomy
6. The effect of subcutaneous administration of buprenorphine with patient controlled analgesia system for postoperative pain relief
7. Patient-controlled intranasal analgesia (PCINA) for the management of postoperative pain: A pilot study
8. Morphine binding to human plasma proteins
9. Pharmacokinetics of morphine and its surrogates VI: Bioanalysis, solvolysis kinetics, solubility, pK'a values, and protein binding of buprenorphine
10. Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood
11. Binding of alfentanil to human alpha 1-acid glycoprotein, albumin and serum
12. Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients
13. Pharmacokinetics of alfentanil in chronic renal failure
14. Plasma concentration and protein binding of alfentanil during high-dose infusion for cardiac surgery
15. Pharmacodynamics of alfentanil. The role of plasma protein binding
16. Disposition of alfentanil in burns patients
17. Target-controlled infusion of alfentanil for postoperative analgesia: Contribution of plasma protein binding to intra-patient and inter-patient variability
18. Sufentanil pharmacokinetics in patients with cirrhosis
19. Pharmacokinetic-pharmacodynamic relationships for opioids in balanced anaesthesia
20. Methadone plasma protein binding: Alterations in cancer and displacement from alpha 1-acid glycoprotein
21. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain
22. Methadone binding to orosomucoid (alpha 1-acid glycoprotein): Determinant of free fraction in plasma
23. Binding of alfentanil to human alpha 1-acid glycoprotein, albumin and serum
24. Methadone plasma protein binding: Alterations in cancer and displacement from alpha 1-acid glycoprotein
25. Binding of d-methadone, 1-methadone, and d1-methadone to proteins in plasma of healthy volunteers: Role of the variants of alpha 1-acid glycoprotein
26. The effects of phenytoin dosage on the induction of alpha 1-acid glycoprotein and antipyrine clearance in the dog
27. Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans
28. Clinical pharmacokinetics of dipyrone and its metabolites
29. Plasma protein binding of dipyrone metabolites in man
30. The uptake of fentanyl by erythrocytes
31. Displacement of thiopental from human serum albumin by associated drugs
32. Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine
33. Plasma concentrations of methadone during postoperative patient-controlled extradural analgesia
34. Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents
35. Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein
36. Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: Evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein
37. Elevated serum concentrations of thyroxine-binding globulin and caeruloplasmin in methadone-maintained patients
38. Influence of plasmaprotein binding on analgesic effect of methadone in rats with spontaneous withdrawal
39. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein
40. DNA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression
41. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells
42. Characterization of multidrug transporters in a normal renal tubular cell line resistant to doxorubicin. Multidrug transporters in the LLC-PK(1) cell line and its resistant counterpart
43. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
44. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule
45. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
46. Isolation of endothelial cells from brain, lung, and kidney: Expression of the multidrug resistance p-glycoprotein isoforms
47. Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine
48. Increased drug delivery to the brain by P-glycoprotein inhibition
49. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
50. Modulation of morphine-6-glucuronide penetration into the brain by P-glycoprotein
51. The role of P-glycoprotein in blood-brain barrier transport of morphine: Transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice
52. Morphine antinociception is enhanced in mdr1a gene-deficient mice
53. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein
54. Antinociceptive effects of morphine-6-glucuronide in homozygous MDR1a P-glyco-protein knockout and in wildtype mice in the hotplate test
55. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine
56. Facilitated uptake of fentanyl, but not alfentanil, by human pulmonary endothelial cells
57. Active transport of fentanyl by the blood-brain barrier
58. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: In vitro studies using the rat everted intestinal sac
59. The effect of rifampin administration on the disposition of fexofenadine
60. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: Evidence of cytochrome P-450 3A and p-glycoprotein induction
61. Immunohistochemical distribution and functional characterization of an organic anion transporting polypeptide 2 (oatp2)
62. Active transport properties of porcine choroid plexus cells in culture
63. Effects of probenecid on brain-cerebrospinal fluid-blood distribution kinetics of E-delta 2-valproic acid in rabbits
64. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier
65. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter
66. Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1
67. Probenecid protects against in vivo acetaminophen-induced nephrotoxicity in male Wistar rats
68. Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisartan
69. Biliary excretion of 17beta-estradiol 17beta-D-glucuronide is predominantly mediated by cMOAT/MRP2
70. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family
71. Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2
72. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1
73. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys
74. Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs
75. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transportel 1
76. Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1
77. Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity
78. Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells
79. Characterization of the transport properties of a quinolone antibiotic, fleroxacin, in rat choroid plexus
80. In vivo cisplatin resistance depending upon canalicular multispecific organic anion transporter (cMOAT)
81. Potentiation of morphine analgesia after pretreatment with probenecid or sulfinpyrazone
82. Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: Involvement of probenecid-sensitive transport
83. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite
84. Codeine analgesia is due to codeine-6-glucuronide, not morphine
85. Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics
86. Codeine and morphine in extensive and poor metabolizers of sparteine: Pharmacokinetics, analgesic effect and side effects
87. The pharmacogenetics of codeine hypoalgesia
88. Human UGT2B7 catalyzes morphine glucuronidation
89. Comparison of stably expressed rat UGT1.1 and UGT2B1 in the glucuronidation of opioid compounds
90. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3
91. Glucuronidation of opioids, carboxylic acid-containing drugs, and hydroxylated xenobiotics catalyzed by expressed monkey UDP-glucuronosyltransferase 2B9 protein
92. Tricyclic antidepressants inhibit opioid receptor binding in human brain and hepatic morphine glucuronidation
93. Effects of naltrexone on pharmacodynamics and pharmacokinetics of intravenously administered morphine in the rat
94. Differential inhibition of hepatic morphine UDP-glucuronosyltransferases by metal ions
95. Differential inhibition of morphine glucuronidation in the 3- and 6- position by ranitidine in isolated hepatocytes from guinea pig
96. Natural (-)- and unnatural (+)-enantiomers of morphine: Comparative metabolism and effect of morphine and phenobarbital treatment
97. The enantioselective glucuronidation of morphine in rats and humans. Evidence for the involvement of more than one UDP-glucuronosyl-transferase isoenzyme
98. Human liver morphine UDP-glucuronyl transferase enantioselectivity and inhibition by opioid congeners and oxazepam
99. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4
100. Methadone N-demethylation in human liver microsomes: Lack of stereoselectivity and involvement of CYP3A4
101. Identification of the pharmacogenetic determinants of alfentanil metabolism: Cytochrome P-450 3A4. An explanation of the variable elimination clearance
102. Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism
103. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation
104. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions
105. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: Implications for interindividual variability in disposition, efficacy, and drug interactions
106. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes
107. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4
108. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
109. Tuberculosis and HIV infection
110. The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression
111. Quetiapine: A new atypical antipsychotic
112. New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone, and mirtazapine
113. Drug-grapefruit juice interactions
114. Changes in the metabolism of three model substrates catalysed by different P450 isozymes when administered as a cocktail to the carbon tetrachloride-intoxicated rat
115. Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients
116. Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam
117. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19
118. Methadone withdrawal when starting an antiretroviral regimen including nevirapine
119. Decreased methadone effect after ritonavir initiation
120. Rifampin-induced methadone withdrawal in AIDS
121. Rifampicin and methadone withdrawal
122. Methadone maintenance and tuberculosis treatment
123. The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone
124. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors
125. Amprenavir: A new human immunodeficiency virus type 1 protease inhibitor
126. The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil
127. The CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of i.v. fentanyl
128. The effect of paracetamol (acetaminophen) on fentanyl metabolism in vitro
129. Fentanyl inhibits metabolism of midazolam: Competitive inhibition of CYP3A4 in vitro
130. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine
131. The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers
132. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone
133. Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides
134. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism
135. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6
136. Pharmacokinetics of selective serotonin reuptake inhibitors: Clinical relevance
137. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo
138. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450
139. Inhibition of desipramine hydroxylation (cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: Relation to drug interactions in vivo
140. Metabolism of the antidepressant mirtazapine in vitro: Contribution of cytochromes P-450 1A2,2D6, and 3A4
141. New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone, and mirtazapine
142. Bupropion plasma levels and CYP2D6 phenotype
143. Newer antidepressants and the cytochrome P450 system
144. Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes
145. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6
146. Effect of sertraline on plasma nortriptyline levels in depressed elderly
147. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver
148. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes
149. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists
150. Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6
151. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: Potent effect on CYP2C19 and CYP2D6
152. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone
153. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo
154. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: In vitro studies using human liver microsomes
155. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism
156. Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan
157. Impact of environmental and genetic factors on codeine analgesia
158. Opioid mechanisms controlling renal function
159. Central mu opioids mediate differential control of urine flow rate and urinary sodium excretion in conscious rats
160. Central mu opioid receptor-mediated changes in renal function in conscious rats
161. Renal effects of TAPP, a highly selective mu-opioid agonist
162. Comparison of the water diuretic activity of kappa receptor agonists and a vasopressin receptor antagonist in dogs
163. Central kappa opioids blunt the renal excretory responses to volume expansion by a renal nerve-dependent mechanism
164. Renal excretory responses produced by the delta opioid agonist, BW373U86, in conscious rats
165. Role of atrial natriuretic factor, hemodynamic changes and renal nerves in the renal effects of intraperitoneal morphine in conscious rats
166. Functional antagonism of morphine analgesia by (+)-pentazocine: Evidence for an anti-opioid sigma 1 system
167. Evaluation of two formulations of dihydrocodeine using patient-controlled analgesia
168. Iontophoretic delivery of morphine for postoperative analgesia
169. Postoperative analgesia with transdermal fentanyl following lower abdominal surgery
170. A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy. Analgesic, respiratory, and pharmacokinetic effects
171. The use of intrathecal morphine for analgesia after posterolateral lumbar fusion: A prospective, double-blind, randomized study
172. Continuous spinal anaesthesia/analgesia for the perioperative management of high-risk patients
173. Effects of intraarticular morphine on analgesic requirements after anterior cruciate ligament repair
174. Comparison of the analgesic effects of intrabursal oxycodone and bupivacaine after acromioplasty
175. Randomised double-blind comparison of morphine vs. a morphine-alfentanil combination for patient-controlled analgesia
176. Comparison of epidurally administered sufentanil, morphine, and sufentanil-morphine combination for postoperative analgesia
177. Intrathecal fentanyl for post-thoracotomy pain
178. Oral transmucosal fentanyl citrate (OTFC) for the treatment of postoperative pain
179. Transdermal fentanyl for postoperative pain management in patients recovering from abdominal gynecologic surgery
180. Postoperative analgesia with parenteral opioids: Does continuous delivery utilizing a transdermal opioid preparation affect analgesic efficacy or patient safety?
181. Effectiveness of morphine by periarticular injections after shoulder arthroscopy
182. Analgesic efficacy of perioperative buccal morphine
183. Alfentanil as an adjuvant to epidural bupivacaine in the management of postoperative pain after laparotomies: Lack of evidence of spinal action
184. Acute opioid tolerance: Intraoperative remifentanil increases postoperative pain and morphine requirement
185. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice
186. Excitatory action of opioid peptides and opiates on cultured hippocampal pyramidal cells
187. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment
188. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate
189. Influence of naloxone on the postoperative analgesic and respiratory effects of buprenorphine
190. Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia
191. Postoperative analgesia with i.v. propacetamol and ketoprofen combination after disc surgery
192. Intravenous ketoprofen for pain relief after total hip or knee replacement
193. Assessment of ketorolac as an adjuvant to fentanyl patient-controlled epidural analgesia after radical retropubic prostatectomy
194. Continuous intravenous administration of ketorolac reduces pain and morphine consumption after total hip or knee arthroplasty
195. Postoperative analgesia with epidural methadone in patients operated for hernia of the lumbar disc
196. Intravenous tenoxicam reduces dose and side effects of PCA morphine in patients after thoracic endoscopic sympathectomy
197. A comparative study of ketorolac and diclofenac on post-laparoscopic cholecystectomy pain
198. Rectal paracetamol has a significant morphine-sparing effect after hysterectomy
199. Pain relief after major gynaecological surgery
200. Diclofenac in the treatment of pain after caesarean delivery. An opioid-saving strategy
201. IV diclofenac in postthoracotomy pain
202. Morphine-sparing effect of diclofenac in cancer pain
203. Postoperative nefopam and diclofenac. Evaluation of their morphine-sparing effect alter upper abdominal surgery
204. Failure of rectal diclofenac to augment opioid analgesia after cholecystectomy
205. The pharmacokinetics and analgesic efficacy of larger dose rectal acetaminophen (40 mg/kg) in adults: A double-blinded, randomized study
206. Randomised, placebo-controlled study of the postoperative analgesic effects of ketoprofen after spinal fusion surgery
207. Morphine-sparing effect of ketoprofen after abdominal surgery
208. Balanced analgesia with intravenous ketorolac and patient-controlled morphine following lower abdominal surgery
209. Evaluation of intravenous ketorolac administered by bolus or infusion for treatment of postoperative pain. A double-blind, placebo-controlled, multicenter study
210. Intravenous ketorolac as an adjunct to patient-controlled analgesia (PCA) for management of postgynecologic surgical pain
211. Intravenous ketorolac as an adjuvant to pediatric patient-controlled analgesia with morphine
212. Intramuscular ketorolac following total hip replacement with spinal anaesthesia and intrathecal morphine
213. The efficacy of intramuscular ketorolac in combination with intravenous PCA morphine for postoperative pain relief
214. Double-blind comparison of the morphine sparing effect of continuous and intermittent i.m. administration of ketorolac
215. Ketorolac and patient controlled analgesia in the treatment of postoperative pain
216. Methods of the use of ketorolac tromethamine in patients during the early postoperative period
217. Dose-response of ketorolac as an adjunct to patient-controlled analgesia morphine in patients after spinal fusion surgery
218. Ketorolac does not decrease postoperative pain in elderly men after transvesical prostatectomy
219. Evaluation of the safety and efficacy of ketorolac versus morphine by patient-controlled analgesia for postoperative pain
220. Comparison of morphine patient-controlled analgesia with and without ketorolac for postoperative analgesia in pediatric orthopedic surgery
221. Ketorolac potentiates morphine in postoperative patient-controlled analgesia
222. Patient-controlled postoperative analgesia in orthopedic surgery: Epidural PCA versus intravenous PCA
223. Pain following iliac crest bone grafting of alveolar clefts
224. Acetaminophen as an adjunct to morphine by patient-controlled analgesia in the management of acute postoperative pain
225. The morphine-sparing effect of propacetamol in orthopedic postoperative pain
226. Efficacy of propacetamol in the treatment of postoperative pain. Morphine-sparing effect in orthopedic surgery. Italian Collaborative Group on Propacetamol
227. Comparison of piroxicam with placebo in the management of pain after total hip replacement
228. Patient-controlled analgesia with tramadol versus tramadol plus lysine acetyl salicylate
229. Sustained-release ibuprofen as an adjunct to morphine patient-controlled analgesia
230. Rectal indomethacin for analgesia after appendicectomy in children
231. The efficacy of intravenous indomethacin in prevention of postoperative pain
232. Indomethacin as a postoperative analgesic for total hip arthroplasty
233. Rectal indomethacin reduces postoperative pain and morphine use after cardiac surgery
234. Indomethacin as adjunct analgesia following open cholecystectomy
235. Intravenous diclofenac coupled with PCA fentanyl for pain relief after total hip replacement
236. Prolonged central intravenous ketorolac continuous infusion in a cancer patient with intractable bone pain
237. Opioid-sparing effect of diclofenac in cancer pain
238. Postoperative pain therapy with 1-methadone and metamizole. A randomized study within the scope of intravenous on-demand analgesia
239. Comparison of parenteral diclofenac and ketoprofen for postoperative pain relief after maxillofacial surgery
240. Differential indications of non-opioid drugs for postoperative analgesia II. Quantification of the analgesic effect of a combination of metamizol plus diclofenac via patient-controlled analgesia
241. Differential administration of non-opioids in postoperative analgesia, I. Quantification of the analgesic effect of metamizole using patient-controlled analgesia
242. Postoperative analgesia after endoscopic abdominal operations. A randomized double-blind study of perioperative effectiveness of metamizole
243. Patient-controlled analgesia with morphine plus lysine acetyl salicylate
244. Does patient-controlled analgesia achieve better control of pain and fewer adverse effects than intramuscular analgesia? A prospective randomized trial
245. Ketorolac as an adjunct to patient-controlled morphine in postoperative spine surgery patients
246. Continuous epidural analgesia with bupivacaine-fentanyl versus patient-controlled analgesia with i.v. morphine for postoperative pain relief after knee ligament surgery
247. Persistently high plasma morphine-6-glucuronide levels despite decreased hourly patient-controlled analgesia morphine use after single-dose diclofenac: Potential for opioid-related toxicity
248. Insidious intoxication after morphine treatment in renal failure: Delayed onset of morphine-6-glucuronide action
249. Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery
250. Antidepressant-induced analgesia in chronic non-malignant pain: A meta-analysis of 39 placebo-controlled studies
251. Thoracic epidural clonidine and morphine for postoperative pain relief
252. Addition of oral clonidine to postoperative patient-controlled analgesia with i.v. morphine
253. Intraoperative clonidine enhances postoperative morphine patient-controlled analgesia
254. Clinical efficacy of oral-transdermal clonidine combinations during the perioperative period
255. Patient-controlled epidural analgesia in labor: The addition of clonidine to bupivacaine-fentanyl
256. Postoperative epidural infusion: A randomized, double-blind, dose-finding trial of clonidine in combination with bupivacaine and fentanyl
257. Controlled analgesia in a burn patient: Fentanyl sparing effect of clonidine
258. Comparison of the analgesic effects of intrathecal clonidine and intrathecal morphine after spinal anaesthesia in patients undergoing total hip replacement
259. Oral clonidine reduces postoperative PCA morphine requirements
260. Intraoperative and postoperative analgesia using intravenous opioid, clonidine and lignocaine
261. Morphine-fluoxetine interactions in healthy volunteers: Analgesia and side effects
262. The antinociceptive effect of trazodone in mice is mediated through both &mgr;opioid and serotonergic mechanisms
263. Serotonin receptor subtypes involved in the spinal antinociceptive effect of 5-HT in rats
264. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity
265. The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms
266. Serotonin receptor subtypes involved in modulation of electrical acupuncture
267. Acute tryptophan depletion blocks morphine analgesia in the cold-pressor test in humans
268. Antinociceptive properties of fenfluramine, a serotonin reuptake inhibitor, in a rat model of neuropathy
269. Cotreatment with racemic fenfluramine inhibits the development of tolerance to morphine analgesia in rats
270. The antinociceptive effect of fluvoxamine
271. Intrathecal amitriptyline. Antinociceptive interactions with intravenous morphine and intrathecal clonidine, neostigmine, and carbamylcholine in rats
272. Enhancement of analgesia from systemic opioid in humans by spinal cholinesterase inhibition
273. Intravenous opioids stimulate norepinephrine and acetylcholine release in spinal cord dorsal horn. Systematic studies in sheep and an observation in a human
274. Postoperative analgesia by intra-articular neostigmine in patients undergoing knee arthroscopy
275. Study of the analgesic effects of galanthamine, a cholinesterase inhibitor
276. NMDA receptor challenge with dextromethorphan - Subjective response, neuroendocrinological findings and possible clinical implications
277. NMDA-receptor antagonists in neuropathic pain: Experimental methods to clinical trials
278. Suppression of neuropathic pain by a naturally-derived peptide with NMDA antagonist activity
279. Suppression of neuropathic pain behavior in rats by a non-psychotropic synthetic cannabinoid with NMDA receptor-blocking properties
280. Modulation of neuropathic pain behavior in rats by spinal disinhibition and NMDA receptor blockade of injury discharge
281. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy. A randomized, controlled, double-blind, crossover, double-dose study
282. Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain
283. Postoperative analgesia with i.v. patient-controlled morphine: Effect of adding ketamine
284. Adding ketamine in a multimodal patient-controlled epidural regimen reduces postoperative pain and analgesic consumption
285. Comparison of morphine and morphine with ketamine for postoperative analgesia
286. Patient-controlled epidural analgesia with morphine or morphine plus ketamine for postoperative pain relief
287. Combined infusions of morphine and ketamine for postoperative pain in elderly patients
288. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)
289. Involvement of direct inhibition of NMDA receptors in the effects of sigma-receptor ligands on glutamate neurotoxicity in vitro
290. Enhancement of the opiate withdrawal response by antipsychotic drugs in guinea-pigs is not mediated by sigma binding sites
291. Phencyclidine receptors and N-methyl-D-aspartate antagonism: Electrophysiologic data correlates with known behaviours
292. A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias
293. Ineffectiveness of dextromethorphan in cancer pain
294. Dextrorphan attenuates responses of spinothalamic tract cells in normal and nerve-injured monkeys
295. Systematic review of outpatient services for chronic pain control
296. Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics
297. Pharmacologic treatment of pain in polyneuropathy
298. Postoperative epidural analgesia for pediatric spine surgery
299. Patient-controlled epidural analgesia during labor: The effects of the increase in bolus and lockout interval
300. Comparison of continuous epidural bupivacaine infusion plus either continuous epidural infusion or patient-controlled epidural injection of fentanyl for postoperative analgesia
301. Epidural bupivacaine-morphine analgesia versus patient-controlled analgesia following abdominal aortic surgery: Analgesic, respiratory, and myocardial effects
302. Pain relief for thoracotomy. Comparison of morphine requirements using an extrapleural infusion of bupivacaine
303. Intermuscular bupivacaine infusion for control of pain after renal surgery: A preliminary report
304. Bupivacaine 0.01% and/or epinephrine 0.5 microg/ml improve epidural fentanyl analgesia after cesarean section
305. Patient-controlled extradural analgesia to compare bupivacaine, fentanyl and bupivacaine with fentanyl in the treatment of postoperative pain
306. Patient-controlled epidural analgesia: Demand dosing
307. Effect of ilioinguinal and iliohypogastric nerve block and wound infiltration with 0.5% bupivacaine on postoperative pain after hernia repair
308. Continuous epidural infusion of ropivacaine for postoperative analgesia after major abdominal surgery: Comparative study with i.v. PCA morphine
309. Comparison of patient-controlled epidural analgesia with and without background infusion after gastrectomy
310. A comparison of levobupivacaine 0.125%, fentanyl 4 microg/mL, or their combination for patient-controlled epidural analgesia after major orthopedic surgery
311. Efficacy of bupivacaine delivered by wound catheter for post-Caesarean section analgesia
312. Postoperative patient-controlled epidural analgesia with opioid bupivacaine mixtures
313. Femoral nerve block and ketorolac in patients undergoing anterior cruciate ligament reconstruction
314. Epidural ropivacaine infusion for postoperative analgesia after major lower abdominal surgery - A dose finding study
315. Addition of bupivacaine to sufentanil in patient-controlled epidural analgesia after lower limb surgery in young adults: Effect on analgesia and micturition
316. Patient-controlled epidural versus intravenous pethidine to supplement epidural bupivacaine after abdominal aortic surgery
317. Intraperitoneal bupivacaine or lidocaine does not provide analgesia after total abdominal hysterectomy
318. Equivalent outcomes during postoperative patient-controlled intravenous analgesia with lidocaine plus morphine versus morphine alone
319. Lignocaine plus morphine in bolus patient-controlled intravenous analgesia lacks postoperative morphine-sparing effect
320. Wound infiltration with local anaesthetic after abdominal hysterectomy
321. Patient-controlled extradural analgesia with bupivacaine, fentanyl, or a mixture of both, after Caesarean section
322. Ilioinguinal iliohypogastric nerve blocks-before or after cesarean delivery under spinal anesthesia?
323. Infiltration of the abdominal wall with local anaesthetic after total abdominal hysterectomy has no opioid-sparing effect
324. Intra-articular morphine and/or bupivacaine in the management of pain after total knee arthroplasty
325. Addition of femoral 3-in-1 blockade to intra-articular ropivacaine 0.2% does not reduce analgesic requirements following arthroscopic knee surgery
326. Flumazenil potentiation of postoperative morphine analgesia
327. Low-dose midazolam reduces the alfentanil demand in elderly but not in young patients during extracorporeal shock wave lithotripsy
328. Patient-controlled drug administration during local anesthesia: A comparison of midazolam, propofol, and alfentanil
329. Possible analgesic effect of vigabatrin in animal experimental chronic neuropathic pain
330. The effects of residual pain on oxygenation and breathing pattern during morphine analgesia
331. Intraoperative and postoperative analgesia using intravenous opioid, clonidine and lignocaine
332. Adjunctive interventions for burn pain control: Comparison of hypnosis and ativan: The 1993 clinical research award
333. Continuous extradural infusion of ropivacaine for prevention of postoperative pain after major orthopaedic surgery
334. Postoperative analgesia after major shoulder surgery with interscalene brachial plexus blockade: Etidocaine versus bupivacaine
335. Pharmacologic treatment of pain in polyneuropathy
336. Treatment options in postherpetic neuralgia
337. Possible analgesic effect of vigabatrin in animal experimental chronic neuropathic pain
338. Synergistic effect between intrathecal non-NMDA antagonist and gabapentin on allodynia induced by spinal nerve ligation in rats
339. Gabapentin use in neuropathic pain syndromes
340. Pharmacologic treatment of pain in polyneuropathy
341. Gabapentin, an adjuvant treatment for neuropathic pain in a cancer hospital
342. Use of gabapentin in pain management
343. Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis
344. Is 200mg lamotrigine daily analgesic or not?
345. Lamotrigine in the treatment of chronic refractory neuropathic pain
346. Efficacy of lamotrigine on sensory symptoms and pain in peripheral neuropathies
347. Effects of lamotrigine on pain-induced chemo-somatosensory evoked potentials
348. Molecular mechanisms of the reversal of imipramine-induced sodium channel blockade by alkalinization in human cardiac myocytes
349. Blockade of cardiac sodium channels by amitriptyline and diphenylhydantoin. Evidence for two use-dependent binding sites
350. Tricyclic antidepressants inhibit voltage-dependent calcium channels
351. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain
352. Epidural verapamil reduces analgesic consumption after lower abdominal surgery
353. Cannabinoid transmission and pain perception
354. Cannabinoids as potential new analgesics
355. Synergistic interactions of endogenous opioids and cannabinoid systems
356. Cannabinoid modulation of dynorphin A: Correlation to cannabinoid-induced antinociception
357. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: Dose-response analysis and receptor identification
358. The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol
359. Irreversible inhibitors of GABA transaminase induce antinociceptive effects and potentiate morphine
360. The impact of audit in a district general hospital on postoperative nausea and vomiting after major gynaecological surgery
361. Influence of promethazine on symptom-therapy scores for nausea during patient-controlled analgesia with morphine
362. A comparison of droperidol and cyclizine in the prevention of postoperative nausea and vomiting associated with patient-controlled analgesia
363. Effect of tropisetron on vomiting during patient-controlled analgesia in children
364. Patient-controlled analgesia with a mixture of pethidine and doxapram hydrochloride. A comparison of the incidence of respiratory dysrhythmias with pethidine alone
365. Prevention of postoperative nausea and vomiting with transdermal hyoscine in children using patient-controlled analgesia
366. Nausea prophylaxis using transdermal scopolamine in the setting of patient-controlled analgesia
367. Comparison of ondansetron and droperidol in reducing postoperative nausea and vomiting associated with patient-controlled analgesia
368. Double-blind, randomized comparison of ondansetron and intraoperative propofol to prevent postoperative nausea and vomiting
369. Combination of ondansetron and droperidol in the prophylaxis of postoperative nausea and vomiting
370. High-dose ondansetron regimen vs droperidol for morphine patient-controlled analgesia
371. Antiemetic efficacy of ondansetron with patient-controlled analgesia
372. Influence of droperidol on nausea and vomiting during patient-controlled analgesia
373. Improving patient-controlled analgesia: Adding droperidol to morphine sulfate to reduce nausea and vomiting and potentiate analgesia
374. Extending patient-controlled analgesia to patient-controlled neuroleptanalgesia
375. Reduction of postoperative nausea and vomiting with the combination of morphine and droperidol in patient-controlled analgesia
376. Addition of droperidol to morphine administered by the patient-controlled analgesia method: What is the optimal dose?
377. Antiemetic efficacy of a droperidol-morphine combination in patient-controlled analgesia
378. Comparison of tramadol and tramadol/droperidol mixture for patient-controlled analgesia
379. Patient-controlled analgesia with morphine and droperidol following caesarean section under spinal anaesthesia
380. Patient-controlled analgesia with a mixture of morphine and droperidol
381. Addition of droperidol to patient-controlled analgesia: Effect on nausea and vomiting
382. Comparison of different methods of administering droperidol in patient-controlled analgesia in the prevention of postoperative nausea and vomiting
383. Extrapyramidal side-effects from droperidol mixed with morphine for patient-controlled analgesia in two children
384. Prophylactic antiemetic therapy with patient-controlled analgesia: A double-blind, placebo-controlled comparison of droperidol, metoclopramide, and tropisetron
385. The prevention of postoperative nausea and vomiting using a combination of ondansetron and droperidol
386. Central anticholinergic syndrome in a pediatric patient following transdermal scopolamine patch placement
387. The effect of dose of dexamethasone for antiemesis after major gynecological surgery
388. Effect of dexamethasone on postoperative emesis and pain
389. Infusions of subhypnotic doses of propofol for the prevention of postoperative nausea and vomiting
390. Apneic oxygenation associated with patient-controlled analgesia
391. Itching after epidural and spinal opiates
392. Cutaneous responses to histamine, compound 48/80, and codeine in patients with chronic renal failure
393. Potentiation of histamine-induced itch and flare responses in human skin by the enkephalin analogue FK-33-824, beta-endorphin and morphine
394. The medullary dorsal horn. A site of action of morphine in producing facial scratching in monkeys
395. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial
396. Plasma from patients with the pruritus of cholestasis induces opioid receptor-mediated scratching in monkeys
397. Naloxone versus nalbuphine infusion for prophylaxis of epidural morphine-induced pruritus
398. Inhibition of epidural morphine-induced pruritus by intravenous droperidol. The effect of increasing the doses of morphine and of droperidol
399. Patient-controlled epidural analgesia after thoracotomy: A comparison of meperidine with and without bupivacaine
400. Analgesic nephropathy
401. Effects of NSAIDs on the kidney
402. Nephrotoxicities of nonsteroidal anti-inflammatory drugs